| Literature DB >> 23485475 |
Beatriz Clares1, Rafael A Biedma-Ortiz, Eva Sáez-Fernández, José C Prados, Consolación Melguizo, Laura Cabeza, Raúl Ortiz, José L Arias.
Abstract
The present investigation aimed to develop magnetoliposome nanoparticles loaded with 5-fluorouracil by following a reproducible thin film hydration technique. The physicochemical characterization (including electron microscopy analysis, dynamic light scattering, infrared spectrometry, X-ray diffractometry, electrophoresis, and surface thermodynamics) suggested that superparamagnetic magnetite nuclei were successfully embedded into a multilamellar lipid vesicle. Magnetic responsiveness of these nanocomposites was quantitatively analyzed by determining the hysteresis cycle and qualitatively confirmed by microscopic visualizations. A high frequency alternating electromagnetic field was further used to define their heating properties. The absence of cytotoxicity in human colon fibroblast CCD-18 and in human colon carcinoma T-84 cell lines and excellent hemocompatibility of these core/shell particles were demonstrated. Additionally, 5-fluorouracil incorporation was investigated by two procedures: (i) entrapment into the nanoparticulate matrix and (ii) surface deposition onto already formed magnetoliposome particles. The former method reported greater drug loading values and a sustained release profile. Interestingly, 5-fluorouracil release was also triggered by the heating properties of the nanoparticles (hyperthermia-triggered drug release). Hence, we put forward that magnetoliposome particles hold important properties, that is, magnetically targeted delivery, hyperthermia inducing capability, high 5-fluorouracil loading capability, and hyperthermia-triggered burst drug release, suggestive of their potential for a combined antitumor therapy against colon cancer.Entities:
Keywords: 5-Fluorouracil; Colon cancer; Combined cancer therapy; Hyperthermia; Magnetic drug targeting; Magnetoliposome; Temperature-triggered drug release
Mesh:
Substances:
Year: 2013 PMID: 23485475 DOI: 10.1016/j.ejpb.2013.01.028
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571